Skip to main content

Advertisement

SpringerLink
Log in

Personalised medicine and population health: breast and ovarian cancer

  • Review
  • Published:
Human Genetics Aims and scope Submit manuscript

Abstract

It has been suggested that a personalised approach to cancer prevention and screening might lead to a new paradigm for cancer control. Various aspects include testing for high-penetrance cancer susceptibility genes and generating personal risks scores, based on panels of single nucleotide polymorphisms. These tests can categorize women into various groupings of risk for cancer prevention (surgery and chemoprevention) cancer screening and prevention of cancer recurrence. In this review, I investigate various claims and come to the conclusion that the approach may be beneficial for the occasional patient but is unlikely to have any impact on reducing the burden of cancer incidence and mortality as whole. Challenges include meeting a high uptake of the test in the population, developing an effective and acceptable intervention and the willingness of healthy women to follow health care provider recommendations. The review focuses on strategies to reduce mortality from breast and ovarian cancer but is potentially applicable to other cancer sites, such as colon, prostate, and endometrial.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Akbari MR, Gojska N, Narod SA (2017) Coming of age in Canada: a study of population-based genetic testing for breast and ovarian cancer. Curr Oncol 24:282–283

    Article  CAS  Google Scholar 

  • André F, Bachelot T, Commo F et al (2014) Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol 15:267–274

    Article  Google Scholar 

  • Baum M (1997) Rethink on screening for breast cancer. Lancet 350:810–811

    Article  CAS  Google Scholar 

  • Biller-Andorno N, Jüni P (2014) Abolishing mammography screening programs? A view from the Swiss Medical Board. N Engl J Med 370:1965–1967

    Article  Google Scholar 

  • Bleyer A, Welch HG (2012 Nov) Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med 22(21):1998–2005 367(

    Article  Google Scholar 

  • Burke W, Zimmern R (2007) Moving beyond ACCE. PHG Foundation, Cambridge

    Google Scholar 

  • Burn J, Bishop DT, Mecklin JP, CAPP2 Investigators et al (2008) Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med 359:2567–2578

    Article  CAS  Google Scholar 

  • Cancer Incidence in Five Continents (2002) IARC Scientific Publications, Lyon

  • CG001 Panel v2.3 HOTSPOT ANALYSIS [Internet]. Contextual Genomics, Vancouver (2016). http://contextualgenomics.com/wp-content/uploads/2016/02/CG001.v2.3_Cancer-Panel-1.pdf

  • Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Doll R et al (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371:303–314

    Article  Google Scholar 

  • Collins FS, Varmus H (2015) A new initiative on precision medicine. N Engl J Med 372:793–795

    Article  CAS  Google Scholar 

  • Cuzick J, Sestak I, Cawthorn S et al (2015a) Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol 16:67–75

    Article  CAS  Google Scholar 

  • Cuzick J, Sestak I, Thorat MA (2015b) Impact of preventive therapy on the risk of breast cancer among women with benign breast disease. Breast. https://doi.org/10.1016/j.breast.2015.07.013

    Article  PubMed  PubMed Central  Google Scholar 

  • Daly MB, Pilarski R, Berry M (2017) NCCN guidelines insights: genetic/familial high-risk assessment: breast and ovarian, version 2.2017. J Natl Compr Cancer Netw 15:9–20

    Article  CAS  Google Scholar 

  • Dobrow MJ, Hagens V, Chafe R, Sullivan T, Rabeneck L. Consolidated principles for screening based on a systematic review and consensus process. CMAJ 2018;190:E422–E429

    Article  Google Scholar 

  • Easton DF, Pooley KA, Dunning AM et al (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447:1087–1093

    Article  CAS  Google Scholar 

  • Finch A, Bacopulos S, Rosen B et al (2014a) Preventing ovarian cancer through genetic testing: a population-based study. Clin Genet 86:496–499

    Article  CAS  Google Scholar 

  • Finch AP, Lubinski J, Møller P et al (2014b) Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 32:1547–1553

    Article  Google Scholar 

  • Fisher B, Costantino JP, Wickerham DL et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371–1388

    Article  CAS  Google Scholar 

  • Gronwald J, Huzarski T, Byrski T et al (2006a) Direct-to-patient BRCA1 testing: the Twoj Styl experience. Breast Cancer Res Treat 100:239–245

    Article  Google Scholar 

  • Gronwald J, Tung N, Foulkes WD et al (2006b) Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer 118:2281–2284

    Article  CAS  Google Scholar 

  • Harismendy O, Schwab RB, Alakus H et al (2013) Evaluation of ultra-deep targeted sequencing for personalized breast cancer care. Breast Cancer Res 15(6):R115

    Article  Google Scholar 

  • Hoskins JM, Carey LA, McLeod HL (2009) CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer 9:576–586

    Article  CAS  Google Scholar 

  • Kotsopoulos J, Lubinski J, Moller P, Hereditary Breast Cancer Clinical Study Group et al (2014) Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers. Breast Cancer Res Treat 143:579–586

    Article  CAS  Google Scholar 

  • Kotsopoulos J, Lubinski J, Gronwald J et al (2015) Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Int J Cancer 137:1136–1146

    Article  CAS  Google Scholar 

  • Kotsopoulos J, Gronwald J, Karlan B, Hereditary Ovarian Cancer Clinical Study Group et al (2018) Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. Gynecol Oncol 150:85–91

    Article  Google Scholar 

  • Kraft P, Wacholder S, Cornelis MC et al (2009) Beyond odds ratios—communicating disease risk based on genetic profiles. Nat Rev Genet 10:264–269

    Article  CAS  Google Scholar 

  • Kurian AW, Lichtensztajn DY, Keegan TH, Nelson DO, Clarke CA, Gomez SL (2014) Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998–2011. JAMA 312:902–914

    Article  CAS  Google Scholar 

  • Kurian AW, Ward KC, Hamilton AS et al (2018) Uptake, results and outcomes of germline multiple-gene sequencing after diagnosis of breast cancer. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2018.0644

    Article  PubMed  Google Scholar 

  • Le Tourneau C, Delord JP, Gonçalves A et al (2015) Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol 16:1324–1334

    Article  Google Scholar 

  • Lerner-Ellis J, Khalouei S, Sopik V, Narod SA (2015) Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer. Expert Rev Anticancer Ther 15:1315–1326

    Article  CAS  Google Scholar 

  • Levy-Lahad E, Lahad A, King MC (2014) Precision medicine meets public health: population screening for BRCA1 and BRCA2. J Natl Cancer Inst 107:420

    Article  Google Scholar 

  • Liede A, Mansfield CA, Metcalfe KA et al (2017) Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment. Breast Cancer Res Treat 165:433–444

    Article  CAS  Google Scholar 

  • Liu YR, Jiang YZ, Yu KD, Shao ZM et al (2015) Different patterns in the prognostic value of age for breast cancer-specific mortality depending on hormone receptor status: a SEER population-based analysis. Ann Surg Oncol 22:1102–1110

    Article  Google Scholar 

  • Mavaddat N, Pharoah PD, Michailidou K et al (2015) Prediction of breast cancer risk based on profiling with common genetic variants. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djv036

    Article  PubMed  PubMed Central  Google Scholar 

  • Menkiszak J, Sopik V, Chudecka-Głaz A et al (2017) The impact of an expanded genetic testing program and selective oophorectomy on the incidence of ovarian cancer in West Pomerania. Clin Genet 91:322–327

    Article  CAS  Google Scholar 

  • Metcalfe KA, Narod SA (2002) Breast cancer risk perception among women who have undergone prophylactic bilateral mastectomy. J Natl Cancer Inst 94:1564–1569

    Article  Google Scholar 

  • Metcalfe KA, Snyder C, Seidel J, Hanna D, Lynch HT, Narod S (2005) The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation. Fam Cancer 4:97–103

    Article  Google Scholar 

  • Metcalfe KA, Birenbaum-Carmeli D, Lubinski J et al (2008) International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 122:2017–2022

    Article  CAS  Google Scholar 

  • Metcalfe KA, Fan I, McLaughlin J et al (2009) Uptake of clinical genetic testing for ovarian cancer in Ontario: a population-based study. Gynecol Oncol 112:68–72

    Article  Google Scholar 

  • Metcalfe KA, Poll A, Royer R et al (2010) Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. J Clin Oncol 28:387–391

    Article  CAS  Google Scholar 

  • Michailidou K, Lindström S, Dennis J et al (2017) Association analysis identifies 65 new breast cancer risk loci. Nature 551:92–94

    Article  Google Scholar 

  • Mørch LS, Hannaford PC, Lidegaard Ø (2018) Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med 378:1265–1266

    PubMed  Google Scholar 

  • Narod SA (2015) Tamoxifen chemoprevention—end of the road? JAMA Oncol 1:1033–1034

    Article  Google Scholar 

  • Narod SA, Sopik V (2018) Is invasion a necessary step for metastases in breast cancer? Breast Cancer Res Treat 169:9–23

    Article  Google Scholar 

  • Narod SA, Iqbal J, Miller A (2015) Why have breast cancer mortality rates declined? J Cancer Policy 5:8–17

    Article  Google Scholar 

  • Nelson HD, Cantor A, Humphrey L et al (2016) Screening for breast cancer: a systematic review to update. The 2009 U.S. Preventive Services Task Force Recommendation [Internet]. Agency for Healthcare Research and Quality, Rockville

    Google Scholar 

  • Norquist BM, Harrell MI, Brady MF et al (2016) Inherited mutations in women with ovarian carcinoma. JAMA Oncol 2:482–490

    Article  Google Scholar 

  • Personalized Risk Stratification for Prevention and Early Detection of Breast Cancer [Internet]. Genome Canada (2018). https://www.genomecanada.ca/en/personalized-risk-stratification-prevention-and-early-detection-breast-cancer

  • Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA (2002) Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 31:33–36

    Article  CAS  Google Scholar 

  • Phillips KA, Milne RL, Rookus MA et al (2013) Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol 31:3091–3099

    Article  CAS  Google Scholar 

  • Reimers LL, Sivasubramanian PS, Hershman D et al (2015) Breast cancer chemoprevention among high-risk women and those with ductal carcinoma in situ. Breast J 21:377–386

    Article  CAS  Google Scholar 

  • Reiner AS, John EM, Brooks JD et al (2013) Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women’s Environmental Cancer and Radiation Epidemiology Study. J Clin Oncol 31:433–439

    Article  Google Scholar 

  • Schmidt KT, Chau CH, Price DK, Figg WD (2016) Precision oncology medicine: the clinical relevance of patient-specific biomarkers used to optimize cancer treatment. J Clin Pharmacol 56:1484–1499

    Article  CAS  Google Scholar 

  • Shieh Y, Eklund M, Madlensky L et al (2017) Breast cancer screening in the precision medicine era: risk-based screening in a population-based trial. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djw290

    Article  PubMed  Google Scholar 

  • Sopik V, Narod SA (2018) The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-018-4796-9

    Article  PubMed  PubMed Central  Google Scholar 

  • Stand Up To Cancer Canada—Canadian Breast Cancer Foundation Dream Team Is Announced, Just One Year After Inaugural Telecast [Internet]. Philadelphia (USA): American Association for Cancer Research (2015). http://www.aacr.org/Newsroom/Pages/News-Release-Detail.aspx?ItemID=768#.VrUoSVMrJsN

  • Stephens PJ, Tarpey PS, Davies H et al (2012) The landscape of cancer genes and mutational processes in breast cancer. Nature 486(7403):400–404

    Article  CAS  Google Scholar 

  • Stockley TL, Oza AM, Berman HK et al (2016) Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. Genome Med 8:109

    Article  Google Scholar 

  • Szender JB, Kaur J, Clayback K, Hutton ML, Mikkelson J, Odunsi K, Dresbold C (2018) Breadth of genetic testing selected by patients at risk of hereditary breast and ovarian cancer. Int J Gynecol Cancer 28:26–33

    Article  Google Scholar 

  • Tabar L (2011) Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. Radiology 260:658–663

    Article  Google Scholar 

  • Tsimberidou AM, Hong DS, Ye Y et al (2017) Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): an MD Anderson Precision Medicine Study. JCO Precis Oncol. https://doi.org/10.1200/PO.17.00002

    Article  PubMed  PubMed Central  Google Scholar 

  • Tsoref D, Panzarella T, Oza A (2014) Aspirin in prevention of ovarian cancer: are we at the tipping point? J Natl Cancer Inst 106:djt453

    Article  Google Scholar 

  • Wagle N, Berger MF, Davis MJ et al (2012) High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov 2(1):82–93

    Article  CAS  Google Scholar 

  • Zhang S, Royer R, Li S et al (2011) Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol 121:353–357

    Article  CAS  Google Scholar 

Download references

Acknowledgements

I thank Victoria Sopik for reviewing the manuscript before submission.

Author information

Authors and Affiliations

  1. Women’s College Research Institute, Women’s College Hospital, 76 Grenville Street, Toronto, ON, M5S 1B2, Canada

    Steven A. Narod

  2. Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada

    Steven A. Narod

Authors
  1. Steven A. Narod
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steven A. Narod.

Ethics declarations

Conflict of interest

The author declares that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

For this type of study, formal consent is not required.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Narod, S.A. Personalised medicine and population health: breast and ovarian cancer. Hum Genet 137, 769–778 (2018). https://doi.org/10.1007/s00439-018-1944-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00439-018-1944-6

Keywords

Search

Navigation